Glutathione for Skin Health

Verdict: Weak, conflicting evidence; does not reliably whiten skin

Oral glutathione is marketed for skin whitening, but the evidence does not support it: any effect is modest, limited to sun-exposed areas, and disappears once you stop. Injectable "whitening drips" have no proven benefit and carry real safety risks.

C 🟠 C Weak Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

The grade reflects a small, low-quality, and contradictory evidence base. The two systematic reviews disagree: one found oral glutathione lowered the melanin index versus placebo but called the effect "moderately efficacious but unsustainable" (PMID 39444151), while a 2019 review reported brightening only in sun-exposed skin, none in sun-protected areas, and concluded the whitening effect is "inconclusive" (PMID 30895708). The single placebo-controlled RCT (n=60, 4 weeks) reached significance at only two of six body sites (PMID 20524875).

The highest-quality appraisal is the most negative: a 2020 evidence-based review judged glutathione "not beneficial enough" as a whitening agent because it worked only in some areas and produced no lasting effect (PMID 32373172), and a critical review framed the practice as largely myth-leaning with limited support (PMID 27088927). A core problem is that oral glutathione is poorly absorbed, since the tripeptide is broken down in the gut, undermining any systemic effect. All studies were small, short, and of undisclosed funding.

Regulators and clinics offer no support. The US FDA has never approved glutathione for skin lightening and warned that supplement-grade powder used in injectable "whitening" drips was contaminated with bacterial endotoxin; UK authorities call cosmetic IV glutathione dangerous and illegal. Major clinics (Mayo, Cleveland Clinic, Harvard) and dermatology bodies do not endorse it. The most evidence-based step for skin tone remains daily broad-spectrum sun protection.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Counter-Evidence
Confidence
84%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.452
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Glutathione as a skin-lightening agent and in melasma: a systematic review
PMID: 39444151 2025 系統性回顧
Finding: Five RCTs plus one open-arm study on oral glutathione showed a significant reduction in melanin index versus placebo; topical 0.5% outperformed 0.1% and placebo; topical 2% plus oral combination was superior to monotherapy. Both topical and oral glutathione produced moderately efficacious but unsustainable skin-lightening; IV glutathione lacked efficacy and was deemed contraindicated.
🟠 Limited quality Effect size: Significant melanin-index reduction vs placebo; effect described as moderate and unsustainable
View on PubMed
The clinical effect of glutathione on skin color and other related skin conditions: A systematic review
PMID: 30895708 2019 系統性回顧
Finding: Both oral glutathione 500 mg/day and topical 2.0% oxidized glutathione brightened skin color in sun-exposed areas; no significant difference in sun-protected areas. Authors conclude current evidence of a skin-whitening effect is still inconclusive due to the quality of included studies and inconsistent findings.
🟠 Limited quality Effect size: Melanin-index reduction limited to sun-exposed sites; overall inconclusive
View on PubMed
Systemic Glutathione as a Skin-Whitening Agent in Adult
PMID: 32373172 2020 Other
Finding: Highest-evidence literature shows glutathione is not beneficial enough as a skin-whitening agent because it was only effective in some parts of the body and did not produce long-lasting effects. Oral preparations were well tolerated; parenteral preparations were not. Evidence does not support widespread use for skin lightening.
🟠 Limited quality Effect size: Effect only in some body sites; not sustained; net assessment negative
View on PubMed
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study
PMID: 20524875 2012 隨機對照試驗 n = 60
Finding: Melanin indices decreased across all six sites in the glutathione group, but statistically significant reductions versus placebo occurred at only two sites (right face p=0.021, sun-exposed left forearm p=0.036). Authors conclude oral glutathione lightens skin color in a small number of subjects, with long-term safety unestablished.
🟠 Limited quality Effect size: Significant only at 2 of 6 sites over 4 weeks
View on PubMed
Glutathione as a skin whitening agent: Facts, myths, evidence and controversies
PMID: 27088927 2016 Other
Finding: Reviews glutathione as a popular systemic skin-lightening molecule. Notes key unanswered questions on treatment duration, longevity of effect and maintenance protocols, and that the FDA of the Philippines issued a public warning against IV glutathione for off-label skin lightening. Frames the practice as largely myth-leaning with limited clinical support.
🟠 Limited quality Effect size: Not quantified; characterized as controversial and unproven
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Against
FDA warns compounders not to use glutathione L-reduced powder distributed by Letco Medical to compound sterile injectable drugs for patients. The L-glutathione powder was labeled with 'Caution: Dietary Supplement' and should not have been used to compound sterile injectable drugs. source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
由圓酵母(Torula yeast)發酵製成之食品原料穀胱甘肽,其每日食用限量為二百五十毫克,且應標示「對穀胱甘肽過敏者、孕婦、哺乳婦女及嬰幼兒應避免食用」之警語字樣。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-skin-health-INT-glutathione-001 繁體中文版 →